Pfizer Investment Co. Ltd.

Researchers used Standard BioTools’ high-content SomaScan® Platform and SomaSignal™ tests for MASH/NASH to identify 69 blood biomarkers that correlate with clinical measures of liver diseaseSOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced a recent paper published in Nature Scientific Reports, by researchers at Pfizer Research and Development, that detailed their use of the high-plex SomaScan® Assay, leveraging an industry-leading 7,000-protein biomarker panel to analyze blood serum samples from patients in a Phase 2a clinical trial for nonalcoholic fatty liver disease (NAFLD) and NASH. Nonalcoholic Fatty Liver Disease, or NAFLD, and nonalcoholic steatohepatitis (NASH) are becoming a global population health concern. Because diagnosing these diseases involves invasive liver biopsies, which can be challenging and expensive, many patients go untested and untreated. These diseases are complex in their impact on the liver, creating lipid accumulations, stiffness in the liver tissue, ballooning of the liver and chronic inflammation. In collaboration with major pharmaceutical companies and leading academic centers, SomaLogic (now Standard BioTools) previously developed serum proteomic SomaSignal™ tests which correlate more faithfully with each component of the liver biopsy than any other noninvasive biomarkers. Because these tests run on the full SomaScan® Platform, covering thousands of protein measurements, the study’s researchers were able to infer liver biopsy effects and identify additional mechanistic pharmacodynamic protein biomarkers to characterize their drug mechanism and measure response in clinical trials. “NASH and NAFLD are a significant challenge in terms of diagnosis and treatment, and the prevalence of metabolic and obesity-related diseases around the world has created a strong sense of urgency to learn more about them and find better ways of treating them,” said Standard BioTools Chief Medical Officer Stephen A. Williams, MD, PhD. “The SomaScan Assay gives us a view of the biological mechanisms of this disease with a simple blood draw from patients, and SomaSignal tests were shown in this study to be valuable in showing disease regression in patients.” The study focused on inhibiting the protein ACC1 using clesacostat, a drug that acts as an acetyl-CoA carboxylase inhibitor. Using the SomaScan Assay, researchers found 69 blood analytes that strongly correlated with clinical measures of liver inflammation and steatosis. They also discovered the expression of these analytes was significantly higher in NASH patients compared to their NAFLD counterparts. Additionally, in 231 patients in the pre-treatment phase, Standard BioTools’ SomaSignal tests were used to measure 37 different analytes that correlate with NASH and NAFLD. The tests helped researchers stratify patients by disease severity, establish a pre-treatment baseline, and monitor the effects of the drug. The 37 analytes were identified by screening thousands of patient samples using the SomaScan Assay. These analytes were shown to have critical differences in NASH and NAFLD patients and were validated against standard clinical measurements. During the 16-week trial, the SomaScan assay and SomaSignal tests were run on serum samples from study participants subjected to a once-per-day dose of clesacostat. The SomaSignal test scores aligned with improvements in liver fat content (steatosis) as measured by proton density fat fraction, or MRI-PDFF. Twenty-seven analytes were found to be significantly reversed upon drug treatment, demonstrating the utility of SomaSignal tests for classification of NASH and the ACC inhibition treatment-induced effects on steatosis. “The SomaScan Platform has been extensively and systematically validated, providing a strong foundation for this important research,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “These researchers also used the powerful SomaSignal tests to better diagnose NASH and NAFLD patients and to study their responses to treatment.” Standard BioTools now offers the new SomaScan 11K Assay, as well as the industry leading single cell proteomics and spatial proteomics solutions (CyTOF® and Hyperion™ platforms), as a comprehensive pharma services offering to customers who are working to identify biomarkers of predictive response, mechanism of action and patient stratification in their studies. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn and YouTube™. For Research Use Only. Not for use in diagnostic procedures. Limited Use Label License and other terms may apply: www.standardbio.com/legal/salesterms. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance; expectations, operational and strategic plans; the merger of the Company and SomaLogic; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits following the merger of the Company and SomaLogic. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, the outcome of any legal proceedings related to the merger; risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; risks that we may not realize expected cost savings from our restructuring, including the anticipated decrease in operational expenses, at the levels we expect; possible restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on our development activities and results of operation; restructuring activities, including our subleasing plans, customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause us to use cash more quickly than we expect or change or curtail some of our plans, or both; risks that our expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in Standard BioTools’ business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to Standard BioTools’ research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ most recent quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 7, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 14, 2023, and in Standard BioTools’ other filings with the SEC, as well as the “Risk Factors” section of SomaLogic’s most recent quarterly report on Form 10-Q filed with the SEC on November 8, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 28, 2023, and in SomaLogic’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. Standard BioTools disclaims any obligation to update these forward-looking statements except as may be required by law. Media ContactEmilia Costales720 798 5054emilia.costales@standardbio.com Investors David Holmesir@standardbio.com

CRANBURY, N.J.--( BUSINESS WIRE )-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is an accomplished industry executive with extensive global pharmaceutical management experience. “ As an industry-leading pharmaceutical executive, I am very pleased to welcome Mikael to our Board of Directors,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. “ His research and development experience will help advance our leading scientific capabilities and contribute to our mission of developing and delivering potentially transformative treatments for patients.” Throughout his career, Dr. Dolsten has held several positions and is currently the Chief Scientific Officer, President, Research & Development (R&D) at Pfizer Inc. (NYSE: PFE), focused on advancing gene therapies, small-molecule medicines, biotherapeutics, and vaccines. Dr. Dolsten’s previous roles include President of Research at Wyeth and Executive Vice President, Head of Worldwide Research at Boehringer Ingelheim, and senior R&D positions at AstraZeneca, Pharmacia, and Upjohn. He is a member of the Board of Overseers for the Scripps Research Institute and a Foreign Member of The Royal Swedish Academy of Engineering Sciences. He also advised the Obama administration on regulatory and drug development issues and then Vice President Biden’s Cancer Moonshot Initiative. “ Rocket has an impressive pipeline of clinical programs which have shown tremendous promise potentially curing genetic disease,” said Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development. “ I am excited to bring my passion and experience to Rocket as it becomes a commercial organization and strives to reach more patients in need.” About Rocket Pharmaceuticals, Inc. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket’s innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives. Rocket’s lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket’s adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, an early-stage program in clinical trials for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death, and a pre-clinical program targeting BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles. For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn , YouTube, and X . Rocket Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements concerning Rocket’s future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as “could,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket’s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory interactions and planned submissions, including the timing and outcome of the FDA’s review of the additional CMC information that Rocket will provide in response to the FDA’s request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket’s ability to establish key collaborations and vendor relationships for its product candidates, Rocket’s ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket’s ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket’s ability to transition to a commercial stage pharmaceutical company, and Rocket’s expectation that its cash, cash equivalents and investments will be sufficient to funds its operations into 2026. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket’s competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket’s ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket’s ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket’s ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2023, filed February 27, 2024 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

NEW YORK, Aug. 13, 2024 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2024 Prix Galien USA Award nominees for "Best Digital Health Solution," "Best Medical Technology," and "Incubators, Accelerators and Equity." Nominees have also been announced for "Best Startup," in partnership with Business France. Winners will be announced during the Prix Galien USA Forum on November 7, 2024, at the Alexandria Center for Life Science in New York City. Nominees for "Best Medical Technology" will be previewed during the Prix Galien USA Forum, before the remaining category winners are announced during the Prix Galien USA Awards Ceremony at the American Museum of Natural History in New York City. Continue Reading (PRNewsfoto/The Galien Foundation) This year marks the tenth anniversary of The Galien Foundation and Business France recognizing global innovators in the "Best Startup" category. This partnership supports global healthcare startups by offering visibility on the American stage and connecting them with major players in the industry in the U.S. and Canada. "Healthcare innovation is a global endeavor, and we are thrilled to celebrate ten years of partnering with The Galien Foundation. Together, we award excellence in life sciences and biopharmaceuticals while fostering relationships between startups, potential collaborators and investors," said Frederic Rossi, CEO Business France North America. New this year, Northwell Health, in collaboration with The Galien Foundation, will serve as a U.S. landing pad for all companies honored with the prestigious Prix Galien Awards in the categories of Best Digital Health Solution, Best Medical Technology, Best Startup and Best Incubator, Accelerator, Equity. This collaboration provides a platform for healthcare innovators recognized by The Galien Foundation to access the U.S. healthcare market with the support and guidance of Northwell Health. "By bringing together brilliant minds and dedicated professionals, we invigorate more research and development, and opportunity for collaboration in the life sciences. This synergy not only accelerates innovation but also brings us closer to even more groundbreaking solutions that can transform patient care, said Bruno Cohen, Chairman of The Galien Foundation. "We look forward to celebrating the power of partnerships and recognizing excellence in innovation with all nominees in November." Best Digital Health Solution (Nominees) Best Medical Technology (Nominees) Incubators, Accelerators and Equity (Nominees) Best Startup (Nominees) The 2024 Prix Galien USA Medical Technology, Digital Health, Incubators, Accelerators and Equity, and Startup Awards Committee is composed of nine renowned leaders from the biomedical industry and academia, responsible for evaluating nominees. The 2024 Prix Galien Sub-Committees and Advisory Boards conduct a pre-screening of all applications before submitting the shortlist of award candidates to the Awards Committee. Prix Galien Medical Technology, Digital Health, Incubators, Accelerators and Equity, and Startup Awards Committee 2024 Kenneth C. FRAZIER Committee Chair, Former Chairman & CEO Merck Roch DOLIVEUX Honorary CEO, UCB Dr. Mikael DOLSTEN Chief Scientific Officer & President, Pfizer Research and Development Alex GORSKY Former CEO & Executive Chairman, Johnson & Johnson Penny HEATON Global Therapeutic Area Head, Vaccines, Janssen Sheri McCOY Board of Directors, AstraZeneca, Former CEO, Avon François MAISONROUGE Senior Managing Director, Evercore Partners Joel S. MARCUS Executive Chairman & Founder, Alexandria Elias ZERHOUNI Former Head of Global R&D, Sanofi Prix Galien Medical Technology Sub-Committee 2024 Lisa EARNHARDT Executive Vice President, Medical Devices, Abbott Robert S. LANGER David H. Koch Institute Professor, Massachusetts Institute of Technology Cato T. LAURENCIN M.D., Ph.D., University Professor, University of Connecticut Steven LESTER M.D., Chief Medical Officer, Mayo Clinic-ASU MedTech Accelerator Michel PAIRET Head of Innovation Unit– Board of Managing Directors, Boehringer Ingelheim Prix Galien Incubators, Accelerators, and Equity Category Sub Committee 2024 Gil BASHE Managing Partner, Chair Global Health and Purpose, FINN Partners Ron COHEN M.D., Founder, President & CEO, Acorda Therapeutics Jamey EDWARDS Former CEO, Emergent Medical Associates Amir KALALI M.D., Chairman & Chief Curator CNS Summit/Co-Chair Decentralized Trial Research Alliance Michelle LONGMIRE M.D., Co-Founder & CEO, Medable Inc. Cheryl PEGUS M.D., Executive Vice President of Health & Wellness, Walmart James PRUTOW J.D., MBA, Advisory Partner – Life Sciences, Molecular Diagnostics, Global Healthcare, PwC Consulting Prix Galien Startup Advisory Board 2024 Gaye BOK Ph.D., Partner, AI and Digital Innovation Fund, Mass General Brigham Christine BRENNAN Ph.D., Managing Director, Vertex Venture HC Elaine Brennan Executive Director, Global Strategic Partnerships, Northwell Health Luba GREENWOOD Managing Partner, Dana Farber Cancer Institute Venture Fund Rodolphe KATRA Ph.D.,Sr. Research Director & Technical Fellow, Medtronic Michael LANGER Founder and Managing Partner at T.Rx Capital Jonathan MARCHADO Managing Director, Samsung Next Detlev MENNERICH Corporate SVP, Global Head of Business Development & Licensing (BD&L), Boehringer Ingelheim Amir NAIBERG Ass. Vice Chancellor, Technology Development Group, UCLA Leighanne OH MS, Life Sciences Investor, Novo Holding Denis PATRIC Ph.D., Emerging Science & Innovation, Partnering, Pfizer Dennis PURCELL Founder, Aisling Capital Uciane SCARLETT Ph.D., Partner, MPM Capital Prix Galien Digital Health Advisory Board 2024 Junaid BAJWA Chief Medical Scientist, Microsoft Research, Microsoft Sachin NANAVATI Head, Industry, Healthcare, Google Jay RAJDA M.D., Clinical Leader, Healthcare, Amazon MaryAnne RIZK Ph.D., Managing Partner, Rizk Management Advisors, Adjunct Professor, Stevens Institute of Technology Steven ROSENBERG Chief Executive Officer, uMotif Daniel VIAL Former Advisor of Sanofi CEO, Healthcare Consultant About The Galien Foundation The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives. The late Professor Elie Wiesel, 1986 Peace Nobel Laureate, is The Honorary Founding President of The Galien Foundation The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries, Africa and an inaugural chapter established in India in 2024. The Prix Galien was created in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. For more information, visit  . Follow the Foundation on social media: Media Contact: Kara Bradley Finn Partners [email protected] 646-213-7243 SOURCE The Galien Foundation